MCX to launch India's first Electricity Futures after SEBI approval
This new electricity derivative will offer a vital hedging tool to power generators, distribution companies (discoms), large industrial users, and financial market participants. Amid rising electricity demand, volatile fuel prices, and evolving energy market dynamics, MCX sees this launch as timely and essential for risk management and price discovery.
The Electricity Futures Contract will: Be traded in 50 MWh lots
Be quoted in INR per MWh (excluding taxes and levies)
Be available for all 12 calendar months, with trading initially open for the near four months
Be cash settled based on the Volume Weighted Average of the Unconstrained Market Clearing Price (UMCP) in the Day Ahead Market (DAM) at Indian Energy Exchange (IEX)
SEBI's Daily Price Limits (DPL) will apply, starting at 6% and extendable to 9%. Margins are set at a minimum of 10% or volatility-based VaR, whichever is higher. Client-level open positions are capped at 3 lakh MWh or 5% of total market-wide open interest—whichever is higher.
The introduction of electricity futures is expected to bring greater liquidity, transparency, and depth to India's evolving power market, while also offering investors a new avenue for portfolio diversification.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
33 minutes ago
- Business Upturn
Nibe signs Technical Collaboration Agreement with Israel's Elbit Systems for PULS rocket system
Nibe Limited has officially entered into a technical collaboration agreement with Israel-based defence technology firm Elbit Systems Land Limited. Signed on July 26, 2025, the agreement focuses on the transfer of license and technology for the Precise & Universal Launch System (PULS), a high-range artillery rocket system. Under this agreement, Elbit will provide Nibe with the necessary know-how and licensing rights to manufacture and assemble the PULS system in India. The system is designed for long-range precision targeting, capable of engaging threats at distances up to 300 kilometers. The collaboration aims to establish a local manufacturing setup for PULS in India, allowing Nibe to take on responsibilities for development, assembly, and integration. The financial terms of the agreement are expected to be finalized within 45 days from the signing date. This is a purely international partnership between two independent entities, with no related party transaction involved. Neither Nibe's promoter group nor its affiliates have any stake or interest in Elbit Systems Land Limited. The agreement aligns with the regulatory requirements under SEBI's disclosure norms. With this development, Nibe Limited expands its presence in the defence manufacturing sector by bringing advanced rocket system capabilities to the domestic market through technology collaboration with a global player. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
4 hours ago
- Business Upturn
Alembic Pharma gets USFDA nod for Carbamazepine Extended-Release Tablets
Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Carbamazepine Extended-Release Tablets USP in strengths of 100 mg, 200 mg, and 400 mg. These tablets are the generic version of Tegretol-XR, a widely used anticonvulsant drug developed by Novartis Pharmaceuticals. Alembic's version is therapeutically equivalent to the original, meaning it meets the same standards for quality, strength, and effectiveness. Carbamazepine Extended-Release Tablets are primarily used to treat seizure disorders and are also prescribed for trigeminal neuralgia, a chronic pain condition affecting the facial nerves. According to IQVIA data, the US market for this drug was valued at approximately $71 million for the 12-month period ending March 2025. With this approval, Alembic now has a total of 225 ANDA approvals from the USFDA, which includes 202 final approvals and 23 tentative approvals. About Alembic Pharmaceuticals Founded in 1907 and headquartered in India, Alembic Pharmaceuticals is a vertically integrated pharmaceutical company known for its strong focus on research and development. It manufactures and markets generic drugs across global markets, with several of its facilities approved by top regulatory bodies including the USFDA. In India, Alembic is a leader in branded generics, with a product portfolio promoted by a field force of over 5,500 professionals. Its products are widely recognized and trusted by healthcare professionals and patients alike. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
5 hours ago
- Business Upturn
Nifty top gainers this week (July 26): Eternal, ICICI Bank, Cipla, HDFC Life, Hindalco Industries and more
By Aman Shukla Published on July 26, 2025, 09:45 IST The Indian stock market wrapped up the week ending July 26, 2025, deep in negative territory, extending its losing streak to a fourth consecutive week — the longest such stretch this year and the first since October 2024. Both benchmark indices — BSE Sensex and Nifty 50 — declined by around 0.5% over the week, weighed down by broader market weakness. The Nifty Midcap 100 dropped 1.5%, significantly underperforming the large-cap peers. However, there was a slight silver lining: Nifty Bank bucked the trend and managed a marginal 0.5% gain. Despite the bearish close to the week, several heavyweight stocks in the Nifty 50 index delivered notable weekly gains. Let's take a closer look at the top 10 losers of the Nifty 50 this week, according to Trendlyne. Eternal — up 20.7% this week, closing at ₹310.6 ICICI Bank — up 3.6% this week, closing at ₹1,477.1 Cipla — up 3.4% this week, closing at ₹1,532.5 HDFC Life Insurance — up 3.1% this week, closing at ₹762.4 Hindalco Industries — up 2.6% this week, closing at ₹693.5 SBI Life Insurance — up 2.4% this week, closing at ₹1,832.1 HDFC Bank — up 2.4% this week, closing at ₹2,004.6 Apollo Hospitals — up 2.3% this week, closing at ₹7,468.5 Bharti Airtel — up 1.9% this week, closing at ₹1,937.9 Titan Company — up 1.8% this week, closing at ₹3,462.8 Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash CiplaEternalHDFC LifeHindalco IndustriesICICI BankStock Market Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
